Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | GALR3 | O60755 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | GSTA1 | P08263 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9450696 | 0.89 | KDM4E (0.62) | DGAT1KDM4EGLACASP1CES2 | |
| SCHEMBL9450697 | 0.89 | KDM4E (0.62) | DGAT1KDM4EGLACASP1CES2 | |
| SCHEMBL2853526 | 0.84 | DGAT1 (0.59) | DGAT1KDM4EGLACASP1CES2 | |
| SCHEMBL29435112 | 0.84 | DGAT1 (0.59) | DGAT1KDM4EGLACASP1CES2 | |
| SCHEMBL20808925 | 0.84 | DGAT1 (0.64) | DGAT1KDM4EGLACASP1CES2 | |
| SCHEMBL3488897 | 0.82 | ALDH1A1 (0.62) | DGAT1KDM4EGLACASP1CES2 | |
| SCHEMBL7370270 | 0.82 | DGAT1 (0.53) | DGAT1KDM4EGLACASP1HPGD | |
| SCHEMBL1175614 | 0.82 | HPGD (0.69) | DGAT1KDM4EGLACASP1CES2 | |
| SCHEMBL13740129 | 0.82 | DGAT1 (0.62) | DGAT1KDM4EGLACASP1CES2 | |
| SCHEMBL5759947 | 0.82 | DGAT1 (0.57) | DGAT1KDM4EGLACASP1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206749-B1 | PHTHALOCYANINE COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2012-11-21 | — | — | EP | disclosed |
| EP-2206749-B1 | PHTHALOCYANINE COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2012-11-21 | — | — | EP | disclosed |
| US-8304536-B2 | Phthalocyanine compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304536-B2 | Phthalocyanine compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-11-06 | — | — | US | disclosed |
| CN-102216321-A | Therapeutic antiviral peptides | INTERMUNE INC | 2011-10-12 | — | — | CN | disclosed |
| EP-2358736-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | Intermune, Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20100228021-A1 | PHTHALOCYANINE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100228021-A1 | PHTHALOCYANINE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2206749-A1 | PHTHALOCYANINE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2010-07-14 | — | — | EP | disclosed |
| EP-2206749-A1 | PHTHALOCYANINE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010045266-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| JP-2003026646-A | METHOD OF PRODUCING 4-BROMOPHTHALONITRILE | SEIKO EPSON CORP | 2003-01-29 | — | — | JP | disclosed |
| WO-1995027692-A1 | SUBTITUTED BIPHENYL TNF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | SARS1, VIP, MAVS | DGAT1 3602/4885KDM4E 4649/4885GLA 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.